Lipoprotein(a) and thromboembolism: current state of knowledge and unsolved issues.

IF 3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Archives of Medical Science Pub Date : 2024-12-13 eCollection Date: 2024-01-01 DOI:10.5114/aoms/197357
Małgorzata Konieczyńska, Joanna Natorska, Michał Ząbczyk, Anetta Undas
{"title":"Lipoprotein(a) and thromboembolism: current state of knowledge and unsolved issues.","authors":"Małgorzata Konieczyńska, Joanna Natorska, Michał Ząbczyk, Anetta Undas","doi":"10.5114/aoms/197357","DOIUrl":null,"url":null,"abstract":"<p><p>Lipoprotein(a) [Lp(a)], a low-density lipoprotein-like particle containing a highly polymorphic apolipoprotein(a) [apo(a)] homologous in > 80% to plasminogen, was identified as a genetically determined independent risk factor for cardiovascular disease. Elevated Lp(a) levels, found in about 20% of Europeans, are strongly linked to higher rates of myocardial infarction, major adverse cardiac events, accelerated plaque progression, ischemic stroke (especially in younger adults), and calcific aortic valve disease. However, its role in venous thromboembolism, including atypical locations like cerebral and retinal vein thrombosis, remains controversial despite several shared mechanisms underlying arterial and venous thromboembolism. The most robust evidence supports antifibrinolytic properties of elevated Lp(a), particularly smaller apo(a) isoforms, which inhibit plasminogen activation mainly by interacting with the tissue-type plasminogen activator, plasminogen, and fibrin. Other prothrombotic mechanisms include increased synthesis of plasminogen activator inhibitor (PAI-1), formation of denser fibrin networks composed of thinner fibers, less susceptible to lysis, increased platelet activation, enhanced oxidation of phospholipids leading to a low-grade proinflammatory state, upregulated tissue factor expression, and suppression of tissue factor pathway inhibitor. Targeted Lp(a) lowering therapies are currently being tested in randomized clinical trials and could potentially have clinically relevant antithrombotic effects, evidenced by the reduced risk of thromboembolism. This review summarizes the available data on the prothrombotic and antifibrinolytic actions of Lp(a), along with clinical evidence for the increased risk of thromboembolic events related to elevated Lp(a). It also introduces new concepts to explain discrepant clinical results regarding venous events, highlighting the impact of oxidized phospholipids on a prothrombotic state under conditions of high Lp(a).</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 6","pages":"1770-1783"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831339/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/aoms/197357","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Lipoprotein(a) [Lp(a)], a low-density lipoprotein-like particle containing a highly polymorphic apolipoprotein(a) [apo(a)] homologous in > 80% to plasminogen, was identified as a genetically determined independent risk factor for cardiovascular disease. Elevated Lp(a) levels, found in about 20% of Europeans, are strongly linked to higher rates of myocardial infarction, major adverse cardiac events, accelerated plaque progression, ischemic stroke (especially in younger adults), and calcific aortic valve disease. However, its role in venous thromboembolism, including atypical locations like cerebral and retinal vein thrombosis, remains controversial despite several shared mechanisms underlying arterial and venous thromboembolism. The most robust evidence supports antifibrinolytic properties of elevated Lp(a), particularly smaller apo(a) isoforms, which inhibit plasminogen activation mainly by interacting with the tissue-type plasminogen activator, plasminogen, and fibrin. Other prothrombotic mechanisms include increased synthesis of plasminogen activator inhibitor (PAI-1), formation of denser fibrin networks composed of thinner fibers, less susceptible to lysis, increased platelet activation, enhanced oxidation of phospholipids leading to a low-grade proinflammatory state, upregulated tissue factor expression, and suppression of tissue factor pathway inhibitor. Targeted Lp(a) lowering therapies are currently being tested in randomized clinical trials and could potentially have clinically relevant antithrombotic effects, evidenced by the reduced risk of thromboembolism. This review summarizes the available data on the prothrombotic and antifibrinolytic actions of Lp(a), along with clinical evidence for the increased risk of thromboembolic events related to elevated Lp(a). It also introduces new concepts to explain discrepant clinical results regarding venous events, highlighting the impact of oxidized phospholipids on a prothrombotic state under conditions of high Lp(a).

脂蛋白(a)和血栓栓塞:目前的知识状况和未解决的问题。
脂蛋白(a) [Lp(a)]是一种低密度脂蛋白样颗粒,含有高度多态的载脂蛋白(a) [apo(a)],在>中与纤溶酶原同源80%,被确定为心血管疾病的遗传决定的独立危险因素。约20%的欧洲人存在Lp(a)水平升高,与心肌梗死、主要心脏不良事件、斑块加速进展、缺血性中风(尤其是年轻人)和钙化性主动脉瓣疾病的发生率升高密切相关。然而,它在静脉血栓栓塞中的作用,包括脑和视网膜静脉血栓形成等非典型部位,仍然存在争议,尽管有几种共同的动脉和静脉血栓栓塞机制。最有力的证据支持升高的Lp(a)的抗纤溶特性,特别是较小的载脂蛋白(a)异构体,其主要通过与组织型纤溶酶原激活剂、纤溶酶原和纤维蛋白相互作用来抑制纤溶酶原的激活。其他的血栓形成机制包括纤溶酶原激活物抑制剂(PAI-1)的合成增加,由更细的纤维组成的更致密的纤维蛋白网络的形成,不易溶解,血小板活化增加,磷脂氧化增强导致低级别的促炎状态,组织因子表达上调,以及组织因子途径抑制剂的抑制。靶向Lp(a)降低疗法目前正在随机临床试验中进行测试,可能具有临床相关的抗血栓作用,血栓栓塞风险的降低证明了这一点。这篇综述总结了现有的关于Lp(a)的血栓形成前和抗纤溶作用的数据,以及与Lp(a)升高相关的血栓栓塞事件风险增加的临床证据。它还引入了新的概念来解释关于静脉事件的不同临床结果,强调在高Lp条件下氧化磷脂对血栓前状态的影响(a)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Archives of Medical Science
Archives of Medical Science 医学-医学:内科
CiteScore
4.90
自引率
7.90%
发文量
139
审稿时长
1.7 months
期刊介绍: Archives of Medical Science (AMS) publishes high quality original articles and reviews of recognized scientists that deal with all scientific medicine. AMS opens the possibilities for young, capable scientists. The journal would like to give them a chance to have a publication following matter-of-fact, professional review by outstanding, famous medical scientists. Thanks to that they will have an opportunity to present their study results and/or receive useful advice about the mistakes they have made so far. The second equally important aim is a presentation of review manuscripts of recognized scientists about the educational capacity, in order that young scientists, often at the beginning of their scientific carrier, could constantly deepen their medical knowledge and be up-to-date with current guidelines and trends in world-wide medicine. The fact that our educational articles are written by world-famous scientists determines their innovation and the highest quality.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信